GlassScriptPhysician profile
Babar Mirza
NPI 1265442875
$1,195.64
in general payments reported to CMS, 2019-2025
21 companies · $35.46 in 2025
The $35.46 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.66 · 2020: $54.19 · 2021: $129 · 2022: $208 · 2023: $513 · 2024: $194 · 2025: $35.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $231.48 | 2023 | Xarelto |
| Pfizer INC. | $152.05 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $136.71 | 2022-2024 | Breztri |
| Abbott Laboratories | $114.16 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $86.72 | 2020-2023 | Verquvo, Steglatro |
| Novartis Pharmaceuticals Corporation | $79.26 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $46.75 | 2022-2023 | Eliquis |
| Glaxosmithkline, LLC. | $45.80 | 2023 | Trelegy Ellipta |
| Lundbeck LLC | $36.45 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $33.70 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $31.99 | 2022-2023 | Injectafer |
| Arbor Pharmaceuticals, INC. | $31.46 | 2019-2021 | |
| Mylan Specialty L.P. | $30.05 | 2022 | |
| Sanofi Pasteur INC. | $28.86 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.00 | 2025 | Xifaxan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $17.08 | 2023 | Impella |
| Amgen INC. | $15.81 | 2023 | Repatha, Otezla |
| Lilly USA, LLC | $15.69 | 2024 | Mounjaro, Zepbound |
| Abbvie INC. | $15.00 | 2021 | |
| Novo Nordisk INC | $14.89 | 2023 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.73 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babar Mirza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.